Bharat Immunologicals and Biologicals Corporation Ltd

BIBCL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹219 cr, stock is ranked 1,584
Moderate RiskStock is 2.87x as volatile as Nifty
52.101.35 (+2.66%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹219 cr, stock is ranked 1,584
Moderate RiskStock is 2.87x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
-12.09
PB RatioPB Ratio
6.44
Dividend YieldDiv. Yield
Sector PESector PE
38.70
Sector PBSector PB
5.18
Sector Div YldSctr Div Yld
0.66%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Bharat Immunologicals and Biologicals Corporation Limited is a biotechnology company that manufactures and produces a range of pharmaceuticals products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

201820192020202136.1987.8768.0287.01-4.25-5.80-10.21-18.12
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Result 
Announced OnNov 15, 2021

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NIL | Download

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NIL | Download

Result 
Announced OnNov 15, 2021

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NIL | Download

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR, Related Party Transaction - NIL | Download

Result 
Announced OnNov 15, 2021

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR | Download

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Submission Of Limited Review Report Of The Quarterly Unaudited Financial Results For The Quarter Ended September 2021 Under Regulation 33(3)(C ) Of LODR | Download

See all events